These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6806465)

  • 1. Relationship between bupropion disposition and dopamine uptake inhibition in rats and mice.
    Butz RF; Welch RM; Findlay JW
    J Pharmacol Exp Ther; 1982 Jun; 221(3):676-85. PubMed ID: 6806465
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs.
    Suckow RF; Smith TM; Perumal AS; Cooper TB
    Drug Metab Dispos; 1986; 14(6):692-7. PubMed ID: 2877828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunoassay and pharmacokinetic profile of bupropion in the dog.
    Butz RF; Schroeder DH; Welch RM; Mehta NB; Phillips AP; Findlay JW
    J Pharmacol Exp Ther; 1981 Jun; 217(3):602-10. PubMed ID: 6785419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of bupropion's mechanism of antidepressant activity.
    Ferris RM; Cooper BR; Maxwell RA
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):74-8. PubMed ID: 6406468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and kinetics of bupropion.
    Schroeder DH
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):79-81. PubMed ID: 6406469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological significance of the species differences in bupropion metabolism.
    Welch RM; Lai AA; Schroeder DH
    Xenobiotica; 1987 Mar; 17(3):287-98. PubMed ID: 3107223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Specifics of participation of dopaminergic and serotoninergic systems of the brain in latent inhibition based on pharmacological models].
    Loskutova LV; Luk'ianenko FIa
    Biull Eksp Biol Med; 1990 Dec; 110(12):616-7. PubMed ID: 2128040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of bupropion: a review.
    Lai AA; Schroeder DH
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):82-4. PubMed ID: 6406470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The disposition of butriptyline in rats, dogs and man.
    Cameron BD; Chasscaud LF; Lewis JD; Taylor T
    Arzneimittelforschung; 1974 Jan; 24(1):93-6. PubMed ID: 4406119
    [No Abstract]   [Full Text] [Related]  

  • 10. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.
    Dhir A; Kulkarni SK
    Eur J Pharmacol; 2007 Jul; 568(1-3):177-85. PubMed ID: 17509558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects.
    Findlay JW; Van Wyck Fleet J; Smith PG; Butz RF; Hinton ML; Blum MR; Schroeder DH
    Eur J Clin Pharmacol; 1981; 21(2):127-35. PubMed ID: 6804243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bupropion: a review of its mechanism of antidepressant activity.
    Ascher JA; Cole JO; Colin JN; Feighner JP; Ferris RM; Fibiger HC; Golden RN; Martin P; Potter WZ; Richelson E
    J Clin Psychiatry; 1995 Sep; 56(9):395-401. PubMed ID: 7665537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The involvement of dopamine in the central actions of bupropion, a new antidepressant [proceedings].
    Canning H; Goff D; Leach MJ; Miller AA; Tateson JE; Wheatley PL
    Br J Pharmacol; 1979 May; 66(1):104P-105P. PubMed ID: 454899
    [No Abstract]   [Full Text] [Related]  

  • 14. Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine.
    Miller DK; Sumithran SP; Dwoskin LP
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1113-22. PubMed ID: 12183670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose.
    Laizure SC; DeVane CL; Stewart JT; Dommisse CS; Lai AA
    Clin Pharmacol Ther; 1985 Nov; 38(5):586-9. PubMed ID: 3931955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice.
    Fuller RW; Hemrick-Luecke SK; Snoddy HD
    J Pharmacol Exp Ther; 1994 Apr; 269(1):132-6. PubMed ID: 7513356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant profiles of bupropion and three metabolites: clinical and pre-clinical studies.
    Golden RN
    Pharmacopsychiatry; 1991 Mar; 24(2):68. PubMed ID: 1953872
    [No Abstract]   [Full Text] [Related]  

  • 18. The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses.
    Posner J; Bye A; Dean K; Peck AW; Whiteman PD
    Eur J Clin Pharmacol; 1985; 29(1):97-103. PubMed ID: 3932079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion.
    Musso DL; Mehta NB; Soroko FE; Ferris RM; Hollingsworth EB; Kenney BT
    Chirality; 1993; 5(7):495-500. PubMed ID: 8240925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine.
    Vann RE; Rosecrans JA; James JR; Philibin SD; Robinson SE
    Brain Res; 2006 Oct; 1117(1):18-24. PubMed ID: 16949560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.